Anavex Life's Rett Syndrome Candidate Shows Promising Biomarker Correlating Efficacy Data

Anavex Life Sciences Corp AVXL has reported a predictive biomarker response from its Phase 2 trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome.
Data showed that ANAVEX2-73 treatment resulted in a significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints - Rett Syndrome Behaviour Questionnaire (RSBQ) and CGI-I (assessment scale for determining the effects of mental health treatment)
Last week, the company announced that ANAVEX2-73 activates the sigma-1 receptor (SIGMAR1), and helping in restoring neural cell homeostasis and promoting neuroplasticity.
In addition, prespecified patients with WT SIGMAR1 in the clinical trial demonstrated a clinically meaningful and statistically significant 14.5-point improvement over placebo in the RSBQ total score.
The treatment demonstrated clinically meaningful and statistically significant 12.9-point improvement in anxiety and mood symptoms scale for ANAVEX2-73 vs. placebo.
Price Action: AVXL shares are up 19.3% at $26.40 during the market trading session on the last check Monday.